To further verify the drug-resistant function of MLL mutation in bladder cancer cells, epirubicin was used in the functional experiments in vitro, which is widely used as a chemotherapeutic drug in intravesical instillation for bladder cancer patients [31]. This evidence concerns the gene KMT2A and urinary bladder carcinoma.